Traneurocin

Originally developed in Russia in 1991 under the name cyclopropyloglycine (CPG) as in an attempt to explore the possibilities that lie ahead for racetam-like drugs, traneurocin remained relatively uknown until recently, when it has been demonstrated as a strong candidate for treatment of Alzheimer’s and other neurological disorders, and has become an emerging star among experimental nootropics.

While traneurocin, currently also known as NA-831, is structurally related to piracetam, a nootropic that doesn’t need an introduction, it also happens to be the major metabolite of omberacetam (noopept). As a synthetic cyclized dipeptide, comprised proline and glycine, it is a small molecule that readily crosses the blood-brain barrier. Surprisingly enough, it has been proven to be an endogenous compound present at low concentrations in rat brain. Whereas it is claimed to possess neuroprotective, neurogenesis-stimulating and nootropic effects, antihypoxic and anxiolytic action has been as well observed.

The mechanism of action of traneurocin has not been fully disclosed, there are, however certain relevant findings on the matter. Traneurocin has been reported to strongly promote neurogenesis by increasing brain-derrived neurotropic factor (BDNF) levels, which could potentially explain its procognitive effects, and has been found to act as a positive allosteric modulator of the AMPA receptor and GABA-A receptor, which could account for its potential as an anxiolytic and anti-depressant.

It has passed phase II trials in patients with mild to moderate Alzheimer’s and mild cognitive impairment (MCI). Phase III trials will not be centered around exclusively treatment of the disease, but also its prevention in high-risk populations.

Patients with Alzheimer’s and mild cognitive impairment treated with traneurocin showed a significant improvement in a wide spectrum of areas: ability to concentrate, short term memory, long term memory, ability to self care, orientation, and cognitive functions. Moreover, their quality of life improved due to other positive changes related to energy levels, sleep quality and emotional well-being.

What makes traneurocin an even more interesting and promising compound is its versatility – it is undergoing advanced trials for the prophylaxis and treatment of COVID-19, Rett’s syndrome and fragile X syndrome. Also, it is currently being developed for the treatment of major depressive disorder. It is, perhaps, worth mentioning that it is specifically targeted to treat COVID-19-induced neuropathy.

Benefits of taking traneurocin

• boost in neurogenesis;
• improved ability to concentrate;
• enhanced short-term and long-term memory;
• lessened anxiety;
• better mood;
• decreased irritability;
• enhanced emotional regulation;
• neuroprotective effects;
• better executive function;
• improvement in COVID-19-induced neuropathy.

Side effects

Traneurocin seems to be remarkably well-tolerated and safe, as no adverse effects or concerning safety signals were reported in its foregoing trials.

Dosage

Traneurocin is taken orally, with a single 30 mg dose per day.